BLTE
Belite Bio Inc

265
Mkt Cap
$6.46B
Volume
1.00
52W High
$200.00
52W Low
$49.00
PE Ratio
-71.42
BLTE Fundamentals
Price
$165.38
Prev Close
$164.11
Open
$164.10
50D MA
$170.99
Beta
0.59
Avg. Volume
193,894.36
EPS (Annual)
-$2.31
P/B
8.38
Rev/Employee
$0.00
$1,782.36
Loading...
Loading...
News
all
press releases
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) has been given an average rating of "Moderate Buy" by the eight ratings firms that are currently covering the stock, MarketBeat Ratings...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference
Belite Bio (NASDAQ:BLTE) Chief Medical Officer Hendrik Scholl outlined the company's approach to treating Stargardt disease and reviewed top-line results from its Phase 3 DRAGON trial during a...
MarketBeat·7d ago
News Placeholder
Belite Bio (BLTE) to Release Earnings on Monday
Belite Bio (NASDAQ:BLTE) will be releasing its Q4 2025 earnings before the market opens on Monday, March 16. (View Earnings Report at...
MarketBeat·8d ago
News Placeholder
Belite Bio (NASDAQ:BLTE) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised Belite Bio from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·10d ago
News Placeholder
Q1 Earnings Forecast for Belite Bio Issued By HC Wainwright
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Free Report) - Stock analysts at HC Wainwright reduced their Q1 2026 EPS estimates for Belite Bio in a research note issued on Tuesday, March 3rd. HC...
MarketBeat·11d ago
News Placeholder
Belite Bio (NASDAQ:BLTE) Price Target Raised to $200.00 at HC Wainwright
HC Wainwright upped their price objective on shares of Belite Bio from $185.00 to $200.00 and gave the stock a "buy" rating in a report on Tuesday...
MarketBeat·14d ago
News Placeholder
Belite Bio (NASDAQ:BLTE) Price Target Raised to $201.00
Morgan Stanley raised their price objective on Belite Bio from $191.00 to $201.00 and gave the stock an "overweight" rating in a research note on Tuesday...
MarketBeat·14d ago
News Placeholder
Belite Bio (NASDAQ:BLTE) Price Target Raised to $266.00 at Cantor Fitzgerald
Cantor Fitzgerald lifted their target price on Belite Bio from $200.00 to $266.00 and gave the stock an "overweight" rating in a research report on Tuesday...
MarketBeat·14d ago
News Placeholder
Belite Bio Q4 Earnings Call Highlights
Belite Bio (NASDAQ:BLTE) used its fiscal fourth quarter and full-year 2025 earnings call to outline regulatory and commercialization plans for tinlarebant in Stargardt disease, provide updates across...
MarketBeat·15d ago
News Placeholder
Belite Bio (NASDAQ:BLTE) Shares Down 8.6% - What's Next?
Belite Bio (NASDAQ:BLTE) Trading Down 8.6% - Should You Sell...
MarketBeat·15d ago
<
1
2
...
>

Latest BLTE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.